Nasal spray to treat anxiety moves forward with global phase 3 trial
VistaGen says FDA found no signal of abuse potential for its nasal spray PH94B for anxiety | Seeking Alpha
PH94B Neuroactive Nasal Spray, a Potential On-Demand Treatment for Social Anxiety Disorder | Learn how PH94B, a novel, rapid-acting CNS neuroactive nasal spray being developed by VistaGen Therapeutics for the treatment of
VistaGen Therapeutics, Inc. (VTGN) Message Board | InvestorsHub
VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder - BioTuesdays
,%20Phobia,%20Social,%20Anxiety%20Disorders:%0A%0APH94B%20Nasal%20Spray%20for%20Social%20Anxiety%20Disorder%20(SAD).png?md=1 "PH94B Nasal Spray for Social Anxiety Disorder (SAD) Clinical Trial 2022 | Power")
PH94B Nasal Spray for Social Anxiety Disorder (SAD) Clinical Trial 2022 | Power
Social Anxiety Disorder | Vistagen Therapeutics, Inc
VistaGen Reports Positive Preclinical Data Differentiating Mechanism of Action of PH94B from Risk-Ridden Benzodiazepines
PH94B Neuroactive Nasal Spray, a Potential On-Demand Treatment for Social Anxiety Disorder - YouTube
Fasedienol - Wikipedia
vtgn10k_mar312020
Nasal spray to treat social anxiety disorder lacks abuse potential: FDA
VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin (NASDAQ:VTGN) | Seeking Alpha
VistaGen's nasal spray wins US FDA fast-track designation for anxiety disorder | S&P Global Market Intelligence
PH94B Nasal Spray for Anxiety Disorders | Vistagen Therapeutics, Inc
:%0A%0APH94B%20Nasal%20Spray%20for%20Anxiety%20Disorders.png?md=1 "PH94B Nasal Spray for Anxiety Disorders Clinical Trial 2022 | Power")
PH94B Nasal Spray for Anxiety Disorders Clinical Trial 2022 | Power
Latest Pharma News Updates | VistaGen, Merck, CAMP4, Wugen, Incyte
#PH94B - Twitter Search / Twitter
Social Interaction Challenge, Minute-by-Minute Subjective Units of... | Download Scientific Diagram
PH94B Nasal Spray for Anxiety Disorders | Vistagen Therapeutics, Inc
VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin (NASDAQ:VTGN) | Seeking Alpha
VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin (NASDAQ:VTGN) | Seeking Alpha
VistaGen Therapeutics, Inc.
PH94B Nasal Spray for Anxiety Disorders | Vistagen Therapeutics, Inc
U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
Psych News Alert: Experimental Nasal Spray May Treat Social Anxiety Disorder, Study Indicates
VistaGen's Nasal Spray for Social Anxiety Disorder Falls Short in Phase III Trial | BioSpace
